Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zelavespib - Samus Therapeutics

Drug Profile

Zelavespib - Samus Therapeutics

Alternative Names: PU-H-71; Purine-scaffold HSP90 inhibitor - Samus Therapeutics

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Samus Therapeutics
  • Class Amines; Antineoplastics; Benzodioxoles; Iodinated hydrocarbons; Organic sulfur compounds; Purines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Myelofibrosis
  • No development reported Acute myeloid leukaemia; Breast cancer; Lymphoma; Solid tumours
  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (IV)
  • 10 Dec 2022 Adverse events data from a phase I trial in Myelofibrosis presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
  • 28 Nov 2022 Samus Therapeutics terminates phase I trial in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (Post-PV MF), and post-essential thrombocytopenia myelofibrosis (Post-ET MF) who are receiving ruxolitinib in the US (NCT03935555)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top